CorVel Corporation Price & Performance (CRVL)

Barclays PLC and RBF Capital recently increased their positions in CorVel, signaling continued institutional interest. Meanwhile, company insiders, including Director Jeffrey Michael and CFO Brandon O’Brien, have trimmed their stakes, collectively selling over 48,000 shares in recent months. Despite insider selling, CorVel’s financials remain strong, and analysts maintain a positive outlook.123

Director Jeffrey Michael’s $1.93 million stock sale follows a year of robust performance for CorVel, which saw a 47.69% return and a 13% revenue jump in the latest quarter. The company’s recent 3-for-1 stock split and ongoing investments in AI-driven healthcare solutions underscore its growth strategy, despite some margin pressures.45

CorVel shares have experienced a 3.03% drop, with trading volatility persisting and technical indicators suggesting further short-term weakness. While long-term signals remain positive, analysts caution that the stock could continue to slide in the coming weeks, reflecting mixed sentiment amid recent insider selling and fluctuating support levels.6